©2024 Stanford Medicine
Erwinase Master Treatment Protocol
Not Recruiting
Trial ID: NCT00590915
Purpose
The purpose of this study is to make Erwinase available to patients with acute lymphoblastic
leukemia (ALL) who have had previous allergic reactions to certain formulations of
L-asparaginase.
Official Title
Erwinase Master Treatment Protocol
Stanford Investigator(s)
Eligibility
Inclusion Criteria:
- Patient must give written informed consent to receive Erwinase.
- Patient must be treated for acute lymphoblastic leukemia.
- Patient must have either systemic hypersensitivity reactions to native (Elspar) or
pegylated E.coli asparaginase (Oncaspar). This includes patients with generalized rash
with or without anaphylactic symptoms, or patients with previously documented local or
systemic reactions to E.coli derived L-asparaginase.
Exclusion Criteria:
- Previous allergic reaction to Erwinia L-asparaginase (Erwinase)
- Previous acute pancreatitis
- Pregnant or lactating woman
Intervention(s):
drug: Erwinia L-asparaginase
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Peds Hem/Onc CRAs
650-723-5535